| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
* Departments of Biochemistry, Erasmus University Medical Center, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands
Cell Biology and Genetics, Erasmus University Medical Center, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands
Vascular Surgery, Erasmus University Medical Center, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands
1 To whom correspondence should be addressed. e-mail: a.vantol{at}erasmusmc.nl; m.decrom{at}erasmusmc.nl
Plasma phospholipid transfer protein (PLTP) transfers phospholipids between lipoproteins and mediates HDL conversion. PLTP-overexpressing mice have increased atherosclerosis. However, mice do not express cholesteryl ester transfer protein (CETP), which is involved in the same metabolic pathways as PLTP. Therefore, we studied atherosclerosis in heterozygous LDL receptor-deficient (LDLR+/–) mice expressing both human CETP and human PLTP. We used two transgenic lines with moderately and highly elevated plasma PLTP activity. In LDLR+/–/huCETPtg mice, cholesterol is present in both LDL and HDL. Both are decreased in LDLR+/–/huCETPtg/huPLTPtg mice (>50%). An atherogenic diet resulted in high levels of VLDL+LDL cholesterol. PLTP expression caused a strong PLTP dose-dependent decrease in VLDL and LDL cholesterol (–26% and –69%) and a decrease in HDL cholesterol (–70%). Surprisingly, atherosclerosis was increased in the two transgenic lines with moderately and highly elevated plasma PLTP activity (1.9-fold and 4.4-fold, respectively), indicating that the adverse effect of the reduction in plasma HDL outweighs the beneficial effect of the reduction in apolipoprotein B (apoB)-containing lipoproteins. The activities of the antiatherogenic enzymes paraoxonase and platelet-activating factor acetyl hydrolase were both PLTP dose-dependently reduced (
–33% and –65%, respectively).
We conclude that expression of PLTP in this animal model results in increased atherosclerosis in spite of reduced apoB-containing lipoproteins, by reduction of HDL and of HDL-associated antioxidant enzyme activities.
Abbreviations: apoB, apolipoprotein B; CETP, cholesteryl ester transfer protein; HFHC, high fat, high cholesterol; LDLR, LDL receptor; PAF-AH, platelet-activating factor acetyl hydrolase; PLTP, phospholipid transfer protein; PON, paraoxonase
Supplementary key words apolipoprotein B • high density lipoprotein • cholesteryl ester transfer protein • cholesterol • transgenic • paraoxonase • platelet activating factor acetyl hydrolase
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Moerland, H. Samyn, T. van Gent, R. van Haperen, G. Dallinga-Thie, F. Grosveld, A. van Tol, and R. de Crom Acute Elevation of Plasma PLTP Activity Strongly Increases Pre-existing Atherosclerosis Arterioscler. Thromb. Vasc. Biol., July 1, 2008; 28(7): 1277 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Minahk, K.-W. Kim, R. Nelson, B. Trigatti, R. Lehner, and D. E. Vance Conversion of Low Density Lipoprotein-associated Phosphatidylcholine to Triacylglycerol by Primary Hepatocytes J. Biol. Chem., March 7, 2008; 283(10): 6449 - 6458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Moerland, H. Samyn, T. van Gent, M. Jauhiainen, J. Metso, R. van Haperen, F. Grosveld, A. van Tol, and R. de Crom Atherogenic, enlarged, and dysfunctional HDL in human PLTP/apoA-I double transgenic mice J. Lipid Res., December 1, 2007; 48(12): 2622 - 2631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Liu, J. Iqbal, C. Yeang, D. Q.-H. Wang, M. M. Hussain, and X.-C. Jiang Phospholipid Transfer Protein-Deficient Mice Absorb Less Cholesterol Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 2014 - 2021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Wehinger, I. Tancevski, W. Schgoer, P. Eller, K. Hochegger, M. Morak, A. Hermetter, A. Ritsch, J. R. Patsch, and B. Foeger Phospholipid Transfer Protein Augments Apoptosis in THP-1-Derived Macrophages Induced by Lipolyzed Hypertriglyceridemic Plasma Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 908 - 915. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Vikstedt, D. Ye, J. Metso, R. B. Hildebrand, T. J.C. Van Berkel, C. Ehnholm, M. Jauhiainen, and M. Van Eck Macrophage Phospholipid Transfer Protein Contributes Significantly to Total Plasma Phospholipid Transfer Activity and Its Deficiency Leads to Diminished Atherosclerotic Lesion Development Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): 578 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Liu, M. R. Hojjati, C. M. Devlin, I. H. Hansen, and X.-C. Jiang Macrophage Phospholipid Transfer Protein Deficiency and ApoE Secretion: Impact on Mouse Plasma Cholesterol Levels and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 190 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Zschenker, T. Illies, and D. Ameis Overexpression of lysosomal Acid lipase and other proteins in atherosclerosis. J. Biochem., July 1, 2006; 140(1): 23 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Dallinga-Thie, A. van Tol, H. Hattori, P. C.N. Rensen, E. J.G. Sijbrands, and for the Diabetes Atorvastatin Lipid Intervention ( Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein e? Diabetes, May 1, 2006; 55(5): 1491 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Aouizerat, M. B. Engler, Y. Natanzon, M. Kulkarni, J. Song, C. Eng, J. Huuskonen, C. Rivera, A. Poon, M. Bensley, et al. Genetic variation of PLTP modulates lipoprotein profiles in hypoalphalipoproteinemia J. Lipid Res., April 1, 2006; 47(4): 787 - 793. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |
